Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
Clinical trial NCT04915755 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04915755
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-28
- Primary completion
- 2024-06-28
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.